Oral Micronized Progesterone Bone Health and Density Impact

What the human bone data actually show

The main human evidence comes from the bone mineral density report of the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, published in JAMA in 1996 [1]. It followed 875 healthy postmenopausal women aged 45 to 64 at seven clinical centers for three years. Participants were assigned to placebo, conjugated equine estrogens (CEE) 0.625 mg daily, CEE plus cyclic medroxyprogesterone acetate (MPA) 10 mg daily for 12 days a month, CEE plus continuous MPA 2.5 mg daily, or CEE plus cyclic micronized progesterone 200 mg daily for 12 days a month [1].

At 36 months, the placebo group had lost an average of 1.8% of spinal bone mineral density and 1.7% of hip BMD. The active regimens gained BMD at both sites, with spinal increases ranging from 3.5% to 5.0% and a mean hip increase of 1.7% [1]. Women on CEE plus continuous MPA gained more spinal BMD (5%) than the other three active regimens, which averaged 3.8%. Among women who adhered to their assigned treatment, there were no significant differences in BMD change among the four active regimens [1].

Two limits on that result are worth stating plainly. The report gives a range for the active regimens rather than a separate figure for the micronized progesterone arm, and estrogen alone was one of the active regimens inside the 3.8% average, so the trial report does not show extra bone density from adding progesterone to estrogen [1]. Every active PEPI regimen used conjugated equine estrogen 0.625 mg daily, not estradiol; the placebo group received placebo pills and no hormones [4][1].

Why progesterone was investigated for bone at all

A 1990 review by Prior in Endocrine Reviews concluded that progesterone appears to act directly on bone through an osteoblast receptor, or indirectly by competing for the glucocorticoid receptor on osteoblasts, and that it may promote bone formation [5]. A 2010 review by Seifert-Klauss and Prior adds that progesterone stimulates osteoblast differentiation in vitro [2]. That is laboratory and physiological evidence; it is not a demonstration of a clinical bone benefit.

Does progesterone build bone without estrogen?

In postmenopausal women with increased bone turnover, the answer from the randomized trials is no. A 2010 review of the evidence reports that in 4 placebo-controlled trials, progesterone did not prevent bone loss in these women [2].

The picture is different before menopause. The same review notes that pooled data from 5 studies show regularly cycling premenopausal women losing BMD in association with subclinical ovulatory disturbances, that cyclic progestin prevents bone loss in healthy premenopausal women with amenorrhea or those disturbances, and that BMD loss is faster in perimenopause than after it [2]. Its overall conclusion is that progesterone prevents bone loss in premenopausal women and possibly in perimenopause [2].

Micronized progesterone versus medroxyprogesterone

On bone, PEPI is the direct comparison: a larger spinal gain for continuous MPA when all participants were counted, and no significant difference among the four active regimens in adherent women [1]. Outside bone, the two progestins separate on lipids. In PEPI, HDL cholesterol fell 0.03 mmol/L on placebo, rose 0.14 mmol/L on CEE alone, rose 0.11 mmol/L on CEE plus cyclic micronized progesterone, and rose 0.03 to 0.04 mmol/L on the MPA regimens [4].

What the Prometrium label says

The labeled indications are narrow: prevention of endometrial hyperplasia in postmenopausal women with a uterus who are receiving conjugated estrogens tablets, and secondary amenorrhea [3]. The label gives the endometrial-protection dose as 200 mg at bedtime for 12 days sequentially per 28-day cycle with daily conjugated estrogens; secondary amenorrhea is treated with 400 mg at bedtime for 10 days [3].

The label says Prometrium may cause transient dizziness and drowsiness and should be taken as a single daily dose at bedtime [3][8]. Peanut allergy is a labeled contraindication because the capsules contain peanut oil, and the label also lists unexplained abnormal genital bleeding, known or suspected breast cancer or a history of it, active or prior deep vein thrombosis or pulmonary embolism, active or prior arterial thromboembolic disease, and known liver dysfunction or disease [3].

The current label, Revision 02/2026, has no boxed warning. Prometrium was one of six menopausal hormone products whose updated labeling FDA approved on 2026-02-12, removing the cardiovascular, breast cancer and probable dementia boxed-warning language; the Women's Health Initiative estrogen-plus-progestin data remain in the label's Warnings and Clinical Studies sections [8][9][10]. That trial used medroxyprogesterone, not micronized progesterone [11].

Fracture outcomes

The large fracture dataset for combined hormone therapy comes from the Women's Health Initiative trial of CEE 0.625 mg plus MPA 2.5 mg in 16,608 postmenopausal women aged 50 to 79. Over an average 5.6 years, 733 women (8.6%) on active treatment and 896 (11.1%) on placebo had a fracture, hazard ratio 0.76 (95% CI 0.69 to 0.83), and total hip BMD rose 3.7% at three years versus 0.14% with placebo [12]. The progestin in that trial was medroxyprogesterone, not micronized progesterone [11][12].

The 2022 position statement of the North American Menopause Society states that hormone therapy has been shown to prevent bone loss and fracture, and that for women younger than 60 or within 10 years of menopause onset the benefit-risk ratio is favorable for prevention of bone loss [13]. FDA likewise notes that randomized studies show women who start hormone therapy within 10 years of menopause have fewer fractures [9].